Showing results (471-480 of 533) with videos related to

Sort By:
Pageof 54
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|December 11, 2008
Imaging patients with suspected brain tumour: guidance for primary careDavid P Kernick, Fayyaz Ahmed, Anish Bahra, et al.
Neurology|June 26, 2024
Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS TrialPeter J Goadsby, Deborah I Friedman, Dagny Holle-Lee, et al.
Cephalalgia : an International Journal of Headache|February 14, 2020
Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatmentDavid W Dodick, Peter J Goadsby, Christian Lucas, et al.
JAMA Neurology|December 20, 2017
Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical TrialVladimir Skljarevski, Tina M Oakes, Qi Zhang, et al.
Neurology|April 29, 2021
Long-term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY StudyPeter J Goadsby, Uwe Reuter, Michel Lanteri-Minet, et al.
The Lancet. Neurology|April 19, 2025
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trialCristina Tassorelli, Rigmor H Jensen, Peter J Goadsby, et al.
Cephalalgia : an International Journal of Headache|June 15, 2023
Two-year, real-world erenumab persistence and quality of life data in 82 pooled patients with abrupt onset, unremitting, treatment refractory headache and a migraine phenotype: New daily persistent headache or persistent post-traumatic headache in the majority of casesAlina Buture, Esther M Tomkins, Arif Shukralla, et al.
The Lancet. Neurology|October 10, 2014
Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trialDavid W Dodick, Peter J Goadsby, Stephen D Silberstein, et al.
The Journal of Headache and Pain|January 16, 2023
Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17-30 monthsEmma Troy, Arif A Shrukalla, Alina Buture, et al.
Cephalalgia : an International Journal of Headache|September 2, 2025
Migraine stigma and general knowledge of migraine: A cross-sectional European surveyPeter J Goadsby, Elena Ruiz de la Torre, Antoinette Maassen van den Brink, et al.
Pageof 54